<DOC>
	<DOCNO>NCT01188603</DOCNO>
	<brief_summary>This trial examine way flibanserin metabolize postmenopausal woman Hypoactive Sexual Desire Disorder .</brief_summary>
	<brief_title>Pharmacokinetics Flibanserin Postmenopausal Women With Hypoactive Sexual Desire Disorder ( HSDD )</brief_title>
	<detailed_description />
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients must stable , monogamous heterosexual relationship least one year . 2 . Patients must primary diagnosis Hypoactive Sexual Desire Disorder least six month . 3 . Patients must naturally postmenopausal woman age least one ovary . 4 . Patients may participate whether currently take systemic hormone therapy provide therapy prescribe treatment low sexual desire . Hormone therapy must stable dose least six month . Exclusion criterion : 1 . Patients history drug dependence abuse within past twelve month . 2 . Patients previously treat flibanserin . 3 . Patients sexual dysfunction Hypoactive Sexual Desire Disorder , : Sexual Aversion Disorder , SubstanceInduced Sexual Dysfunction , Dyspareunia , Vaginismus , Gender Identity Disorder , Paraphilia , Sexual Dysfunction due general medical condition . 4 . Patients indicate sexual partner inadequately treat organic psychosexual dysfunction could interfere patient response treatment . 5 . Patients whose sexual function impair , investigator opinion , abdominal vaginal hysterectomy , oophorectomy pelvic , vaginal , urologic surgery . 6 . Patients pelvic pain , pelvic inflammatory disease , endometriosis , urinary tract vaginal infection/vaginitis , cervicitis , interstitial cystitis , vulvodynia , symptomatic vaginal atrophy gynecological pathology require evaluation . 7 . Patients history unexplained vaginal bleeding within past twelve month . 8 . Patients history Major Depressive Disorder within six month prior Screening ; ; active suicidal ideation intent past ten year suicidal behavior time . 9 . Patients history psychiatric disorder could impact sexual function , increase risk patient safety , impair patient compliance . Such disorder include limited bipolar disorder , psychotic disorder , severe anxiety , eat disorder , antisocial personality disorder . 10 . Clinically significant electrocardiogram abnormality Screening . 11 . Patients history dementia neurodegenerative disease ; organic brain disease ; stroke ; transient ischemic attack ; multiple sclerosis ; spinal cord injury ; brain surgery ; significant brain trauma ; peripheral neuropathy ; epilepsy . 12 . Patients ongoing hepatic impairment ( cirrhosis , hepatic tumor , hepatic disease ) ; peptic ulcer within six month prior Screening ; elevate liver enzymes ; inflammatory bowel disease ; gastrointestinal bleeding within two month prior Screening ; Patients bariatric surgery obesity . 13 . Patients history angina ; atherosclerotic cardiovascular disease ; congestive heart failure ; cardiomyopathy ; symptomatic cardiac valve disease ; arrhythmia ; hypertension . 14 . Patients history renal failure ; know history chronic glomerulonephritis . 15 . Patients history chronic obstructive pulmonary disease , chronic bronchitis , asthma well control medication take twice daily less . 16 . Patients history gonadotrophic hormone disorder uncontrolled diabetes mellitus . 17 . Uncorrected hypothyroidism hyperthyroidism . 18 . Patients history uncontrolled glaucoma . 19 . Patients know Human Immunodeficiency Virus infection , Acquired Immunodeficiency Syndrome , clinically significant immunological disorder autoimmune disorder lupus scleroderma . 20 . Patients history cancer within past ten year , noninvasive , previously resect basal cell carcinoma skin .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>